What is NATROX Wound Care?
NATROX Wound Care operates at the intersection of medical device innovation and patient-centric healthcare. By focusing on the development of transformative technologies designed to restore hope to patients suffering from complex wound conditions, the company has established a robust market position. Their operational philosophy, which balances clinical rigor with a deep commitment to customer outcomes, has enabled them to scale effectively within the competitive life sciences sector. As a key player in the wound management space, NATROX leverages its technological edge to provide scalable, evidence-based interventions that address the unmet needs of millions worldwide.
How much funding has NATROX Wound Care raised?
NATROX Wound Care has raised a total of $61.3M across 4 funding rounds:
Unspecified
$9.1M
Series A
$9.7M
Series C
$9.6M
Series C
$33M
Unspecified (2020): $9.1M with participation from Puhua Capital, Boundary Capital, Amadeus Capital Partners, and Praetura Ventures
Series A (2020): $9.7M led by Praetura Capital
Series C (2022): $9.6M supported by Wealth Club
Series C (2024): $33M featuring Amadeus Capital Partners, Meltwind, and Puhua Capital
Key Investors in NATROX Wound Care
Amadeus Capital Partners
A London-based global technology venture capital firm that invests in high-growth companies across sectors such as digital health, artificial intelligence, and deep tech.
Puhua Capital
An early-stage growth-equity firm founded in 2004 that provides industry resources, management experience, and investment funds to high-potential enterprises.
Boundary Capital
An impact investment fund focusing on high-growth private technology companies, led by partners with deep expertise in life sciences, AI, and engineering.
What's next for NATROX Wound Care?
Following this major enterprise-level funding, NATROX Wound Care is poised to transition into a phase of accelerated commercial expansion and product development. The strategic allocation of these resources will likely focus on scaling manufacturing capabilities, expanding global distribution networks, and deepening clinical research initiatives. By leveraging the expertise of its diverse investor base, the company is expected to solidify its leadership in the digital health and wound care markets, ensuring that its innovative technology reaches a broader patient demographic while maintaining the high standards of care that define its brand identity.
See full NATROX Wound Care company page
